In-depth analysis of the monthly dosage and cost of adagrasib

Adagrasib (Adagrasib), a small molecule inhibitor targeting KRAS G12C mutations, has brought new treatments to various forms of cancer, especially in the treatment of non-small cell lung cancer (NSCLC). Its efficacy is particularly significant. KRAS G12C mutation can cause abnormal cell proliferation, and adagrasib can effectively inhibit the growth and proliferation of tumor cells by blocking this mechanism.

When discussing the dosage and cost of adagrasib, you first need to understand its clinical use guidelines. According to the guidelines, the recommended dose of adagrasiib is 600 mg twice daily until disease progression or intolerable toxicity occurs. This dosing regimen ensures a stable concentration of the drug in the body, thereby maintaining its therapeutic effect.

Regarding the dosage of adagrasib, we need to pay attention to its packaging specifications. At present, the specification of the US version of the original drug is 200mg*180 tablets per box. Based on the daily dosage, it can be calculated that patients need to use approximately 1 box of adagrasib a month. However, the original drugs sold overseas are expensive, which may be as high as 180,000 yuan (the price is affected by the exchange rate and may fluctuate), which undoubtedly brings a heavy financial burden to many patients.

With the advancement of pharmaceutical technology, generic versions of adagrasib have become available. According to the latest news, the first overseas generic drug of adagrasibu has been launched, with a specification of 200mg*90 tablets per box. Compared with original drugs, the price of generic drugs is more affordable, and the price of each box may be more than 4,000 yuan (the price is affected by the exchange rate and may fluctuate). Therefore, patients who use generic drugs need to use about 2 boxes a month, and the cost may be less than 10,000 yuan. For more information on overseas drug prices and related information, please consult Yaode Medical Consultant.